User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells

Primary tabs

download
  • Open access
  • PDF
  • 1.00 M
Hanoteau, Aurélie Henin, Coralie Svec, David Bisilliat Donnet, Charlotte Denanglaire, Sébastien Van den Eynde, Benoît [UCL] Moser, Muriel

(eng) An important question is how chemotherapy may (re-)activate tumor-specific immunity. In this study, we provide a phenotypic, functional and genomic analysis of tumor-specific CD8+ T cells in tumor (P815)-bearing mice, treated or not with cyclophosphamide. Our data show that chemotherapy favors the development of effector-type lymphocytes in tumor bed, characterized by higher KLRG-1 expression, lower PD-1 expression and increased cytotoxicity. This suggests re-engagement of T lymphocytes into the effector program. IFN-I appears involved in this remodeling. Our findings provide some insight into how cyclophosphamide regulates the amplitude and quality of tumor-specific immune responses.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2017
Language Anglais
Journal information "OncoImmunology" - Vol. 6, no. 8, p. e1318234 [1-10] (2017)
Peer reviewed yes
Publisher Taylor & Francis ((United States) Philadelphia, PA)
issn 2162-4011
e-issn 2162-402X
Publication status Publié
Affiliations UCL - SSS/DDUV - Institut de Duve
UCL - SSS/DDUV/GECE - Génétique cellulaire
Keywords Immunology ; Immunology and Allergy ; Oncology ; CD8+ T cells ; Cyclophosphamide ; Effector function ; Exhaustion ; Tumor-specific immunity
Links
  1. Abu Eid R., Razavi G. S. E., Mkrtichyan M., Janik J., Khleif S. N., Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed, 10.1158/2326-6066.cir-16-0048
  2. Suzuki Eiji, Sun Jing, Kapoor Veena, Jassar Arminder S, Albelda Steven M., Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects, 10.4161/cbt.6.6.4090
  3. Denkert Carsten, Loibl Sibylle, Noske Aurelia, Roller Marc, Müller Berit Maria, Komor Martina, Budczies Jan, Darb-Esfahani Silvia, Kronenwett Ralf, Hanusch Claus, von Törne Christian, Weichert Wilko, Engels Knut, Solbach Christine, Schrader Iris, Dietel Manfred, von Minckwitz Gunter, Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer, 10.1200/jco.2009.23.7370
  4. Fridman W. H., Galon J., Pages F., Tartour E., Sautes-Fridman C., Kroemer G., Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates, 10.1158/0008-5472.can-11-1316
  5. Galluzzi Lorenzo, Buqué Aitziber, Kepp Oliver, Zitvogel Laurence, Kroemer Guido, Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents, 10.1016/j.ccell.2015.10.012
  6. Hanoteau Aurélie, Henin Coralie, Moser Muriel, L’immunothérapie au service de la chimiothérapie, de nouvelles avancées, 10.1051/medsci/20163204013
  7. Ge Q., Hu H., Eisen H. N., Chen J., Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments, 10.1073/pnas.052714099
  8. Gattinoni Luca, Finkelstein Steven E., Klebanoff Christopher A., Antony Paul A., Palmer Douglas C., Spiess Paul J., Hwang Leroy N., Yu Zhiya, Wrzesinski Claudia, Heimann David M., Surh Charles D., Rosenberg Steven A., Restifo Nicholas P., Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+T cells, 10.1084/jem.20050732
  9. Goldrath Ananda W., Bogatzki Lisa Y., Bevan Michael J., Naive T Cells Transiently Acquire a Memory-like Phenotype during Homeostasis-Driven Proliferation, 10.1084/jem.192.4.557
  10. Bilsborough J, J Immunol, 162, 3534 (1999)
  11. Rahir Gwendoline, Wathelet Nathalie, Hanoteau Aurélie, Henin Coralie, Oldenhove Guillaume, Galuppo Adrien, Lanaya Hanane, Colau Didier, Mackay Charles R., Van den Eynde Benoit, Moser Muriel, Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2Kd-specific CD8+T cells : Rejection of established p815 mastocytoma, 10.1002/ijc.28617
  12. Sarkar Surojit, Kalia Vandana, Haining W. Nicholas, Konieczny Bogumila T., Subramaniam Shruti, Ahmed Rafi, Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates, 10.1084/jem.20071641
  13. Wiesel Melanie, Crouse Josh, Bedenikovic Gregor, Sutherland Andrew, Joller Nicole, Oxenius Annette, Type-I IFN drives the differentiation of short-lived effector CD8+T cells in vivo : Cellular immune response, 10.1002/eji.201142091
  14. Apetoh Lionel, Smyth Mark J., Drake Charles G., Abastado Jean-Pierre, Apte Ron N., Ayyoub Maha, Blay Jean-Yves, Bonneville Marc, Butterfield Lisa H., Caignard Anne, Castelli Chiara, Cavallo Federica, Celis Esteban, Chen Lieping, Colombo Mario P., Comin-Anduix Begoña, Coukos Georges, Dhodapkar Madhav V., Dranoff Glenn, Frazer Ian H., Fridman Wolf-Hervé, Gabrilovich Dmitry I., Gilboa Eli, Gnjatic Sacha, Jäger Dirk, Kalinski Pawel, Kaufman Howard L., Kiessling Rolf, Kirkwood John, Knuth Alexander, Liblau Roland, Lotze Michael T., Lugli Enrico, Marincola Francesco, Melero Ignacio, Melief Cornelis J., Mempel Thorsten R., Mittendorf Elizabeth A., Odun Kunle, Overwijk Willem W., Palucka Anna Karolina, Parmiani Giorgio, Ribas Antoni, Romero Pedro, Schreiber Robert D., Schuler Gerold, Srivastava Pramod K., Tartour Eric, Valmori Danila, van der Burg Sjoerd H., van der Bruggen Pierre, van den Eynde Benoît J., Wang Ena, Zou Weiping, Whiteside Theresa L., Speiser Daniel E., Pardoll Drew M., Restifo Nicholas P., Anderson Ana C., Consensus nomenclature for CD8+T cell phenotypes in cancer, 10.1080/2162402x.2014.998538
  15. Cruz-Guilloty Fernando, Pipkin Matthew E., Djuretic Ivana M., Levanon Ditsa, Lotem Joseph, Lichtenheld Mathias G., Groner Yoram, Rao Anjana, Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs, 10.1084/jem.20081242
  16. Boissonnas Alexandre, Fetler Luc, Zeelenberg Ingrid S., Hugues Stéphanie, Amigorena Sebastian, In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor, 10.1084/jem.20061890
  17. Schiavoni G., Sistigu A., Valentini M., Mattei F., Sestili P., Spadaro F., Sanchez M., Lorenzi S., D'Urso M. T., Belardelli F., Gabriele L., Proietti E., Bracci L., Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis, 10.1158/0008-5472.can-10-2788
  18. Greyer Marie, Whitney Paul G., Stock Angus T., Davey Gayle M., Tebartz Christina, Bachem Annabell, Mintern Justine D., Strugnell Richard A., Turner Stephen J., Gebhardt Thomas, O’Keeffe Meredith, Heath William R., Bedoui Sammy, T Cell Help Amplifies Innate Signals in CD8 + DCs for Optimal CD8 + T Cell Priming, 10.1016/j.celrep.2015.12.058
  19. Zitvogel Laurence, Galluzzi Lorenzo, Kepp Oliver, Smyth Mark J., Kroemer Guido, Type I interferons in anticancer immunity, 10.1038/nri3845
  20. Olson Janelle A., McDonald-Hyman Cameron, Jameson Stephen C., Hamilton Sara E., Effector-like CD8+ T Cells in the Memory Population Mediate Potent Protective Immunity, 10.1016/j.immuni.2013.05.009
  21. Chu H. Hamlet, Chan Shiao-Wei, Gosling John Paul, Blanchard Nicolas, Tsitsiklis Alexandra, Lythe Grant, Shastri Nilabh, Molina-París Carmen, Robey Ellen A., Continuous Effector CD8 + T Cell Production in a Controlled Persistent Infection Is Sustained by a Proliferative Intermediate Population, 10.1016/j.immuni.2016.06.013
  22. Ahmadzadeh M., Johnson L. A., Heemskerk B., Wunderlich J. R., Dudley M. E., White D. E., Rosenberg S. A., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, 10.1182/blood-2008-12-195792
  23. Odorizzi Pamela M., Pauken Kristen E., Paley Michael A., Sharpe Arlene, Wherry E. John, Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+T cells, 10.1084/jem.20142237
  24. Tessmer M. S., Fugere C., Stevenaert F., Naidenko O. V., Chong H. J., Leclercq G., Brossay L., KLRG1 binds cadherins and preferentially associates with SHIP-1, 10.1093/intimm/dxm004
  25. Henson S. M., Franzese O., Macaulay R., Libri V., Azevedo R. I., Kiani-Alikhan S., Plunkett F. J., Masters J. E., Jackson S., Griffiths S. J., Pircher H.-P., Soares M. V. D., Akbar A. N., KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells, 10.1182/blood-2009-01-199588
  26. Kanakry Christopher G, Ganguly Sudipto, Luznik Leo, Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent, 10.4161/2162402x.2014.974393
  27. Schiavoni G, Blood, 95, 2024 (2000)
  28. Corrales Leticia, McWhirter Sarah M., Dubensky Thomas W., Gajewski Thomas F., The host STING pathway at the interface of cancer and immunity, 10.1172/jci86892
  29. Harlin H., Meng Y., Peterson A. C., Zha Y., Tretiakova M., Slingluff C., McKee M., Gajewski T. F., Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment, 10.1158/0008-5472.can-08-2281
  30. Fuertes Mercedes B., Kacha Aalok K., Kline Justin, Woo Seng-Ryong, Kranz David M., Murphy Kenneth M., Gajewski Thomas F., Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells, 10.1084/jem.20101159
  31. Sikora A. G., Jaffarzad N., Hailemichael Y., Gelbard A., Stonier S. W., Schluns K. S., Frasca L., Lou Y., Liu C., Andersson H. A., Hwu P., Overwijk W. W., IFN-  Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity, 10.4049/jimmunol.0802982
  32. Hanoteau Aurélie, Moser Muriel, Chemotherapy and immunotherapy: A close interplay to fight cancer?, 10.1080/2162402x.2016.1190061
  33. Gros Alena, Parkhurst Maria R, Tran Eric, Pasetto Anna, Robbins Paul F, Ilyas Sadia, Prickett Todd D, Gartner Jared J, Crystal Jessica S, Roberts Ilana M, Trebska-McGowan Kasia, Wunderlich John R, Yang James C, Rosenberg Steven A, Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients, 10.1038/nm.4051
  34. Rizvi N. A., Hellmann M. D., Snyder A., Kvistborg P., Makarov V., Havel J. J., Lee W., Yuan J., Wong P., Ho T. S., Miller M. L., Rekhtman N., Moreira A. L., Ibrahim F., Bruggeman C., Gasmi B., Zappasodi R., Maeda Y., Sander C., Garon E. B., Merghoub T., Wolchok J. D., Schumacher T. N., Chan T. A., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, 10.1126/science.aaa1348
  35. Pauken K. E., Sammons M. A., Odorizzi P. M., Manne S., Godec J., Khan O., Drake A. M., Chen Z., Sen D. R., Kurachi M., Barnitz R. A., Bartman C., Bengsch B., Huang A. C., Schenkel J. M., Vahedi G., Haining W. N., Berger S. L., Wherry E. J., Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade, 10.1126/science.aaf2807
Bibliographic reference Hanoteau, Aurélie ; Henin, Coralie ; Svec, David ; Bisilliat Donnet, Charlotte ; Denanglaire, Sébastien ; et. al. Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells. In: OncoImmunology, Vol. 6, no. 8, p. e1318234 [1-10] (2017)
Permanent URL http://hdl.handle.net/2078.1/194328